No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Illumina, Inc. specializes in delivering advanced sequencing and array technologies designed for genetic and genomic examination. These offerings cater to a diverse array of markets, fostering the widespread use of genomic insights across both research laboratories and clinical environments. Key application areas include life sciences, cancer diagnostics, reproductive medicine, agricultural science, and various nascent fields. The company's portfolio encompasses specialized instrumentation and associated consumables vital for genetic analysis. Additionally, it offers comprehensive genotyping and sequencing services, extends instrument maintenance contracts, and engages in development and licensing partnerships, alongside providing cancer screening services. Illumina's client base is extensive, comprising genomic research facilities, universities, state-funded laboratories, and healthcare providers. It also serves pharmaceutical firms, biotechnology companies, commercial molecular diagnostics providers, and businesses focused on consumer genomics. Globally, Illumina distributes its products through direct sales channels in North America, Europe, Latin America, and the Asia-Pacific. Furthermore, it leverages third-party life-science distributors to reach markets across Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
www.illumina.comNo one on the platform currently holds 0J8Z.L.
No tracked institution reports a position in 0J8Z.L as of their last filing.
No one on the platform has traded 0J8Z.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 19.9% | — | — | — | ||
| Rev. Growth % | -0.7% | 6.0% | ||||
| Profit Margin % | 19.6% | -22.7% | 0.5% | |||
| Free Cash Flow Margin % | 21.4% | 10.0% | 16.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.6B | +7.5% | $5.35 | $5.24–$5.46 | — | 1 |
| 2027 | $4.9B | +6.2% | $6.08 | $5.95–$6.21 | — | 1 |
| 2028 | $5.3B | +7.2% | $7.02 | $6.87–$7.16 | — | 1 |
| 2029 | $5.7B | +9.0% | $8.07 | $7.90–$8.24 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $1.23 | $1.31 | +6.5% |
| 2026-04-30 | $1.05 | $1.15 | +9.5% |
| 2026-02-05 | $1.24 | $1.35 | +8.9% |
| 2025-10-30 | $1.17 | $1.34 | +14.5% |
| 2025-07-31 | $1.01 | $1.19 | +17.8% |
| 2025-05-08 | $0.94 | $0.97 | +3.2% |
| 2025-02-06 | $0.91 | $0.95 | +4.1% |
| 2024-11-04 | $0.88 |
| $1.14 |
| +29.7% |
| $24.6B |
| — |
| 0JSY.LLabcorp Holdings Inc. | $320.14 | +2.83% | $26.4B | — |
| 0K6R.LNeurocrine Biosciences, Inc. | $148.00 | -1.56% | $14.8B | — |
Source: Financial Modeling Prep · peers by sector/industry